News Articles Tagged: Cannabis Use Disorder

AEF0117: A Next-Generation Therapeutic for Cannabis Use Disorder

Explore the next-generation therapeutic potential of AEF0117 for Cannabis Use Disorder (CUD), focusing on its unique CB1 receptor modulation and clinical trial outcomes, with contributions from NINGBO INNO PHARMCHEM CO.,LTD.

Advancing Cannabis Use Disorder Treatment: The Promise of AEF0117

Discover how AEF0117, a novel CB1-SSi, is showing promise in the treatment of Cannabis Use Disorder (CUD). Insights from research and development supported by NINGBO INNO PHARMCHEM CO.,LTD.

Clinical Trials of AEF0117: A Promising Development for Cannabis Use Disorder

An in-depth look at the clinical trial data for AEF0117, a novel CB1 receptor signaling-specific inhibitor, and its implications for treating Cannabis Use Disorder (CUD). Presented by NINGBO INNO PHARMCHEM CO.,LTD., this analysis covers Phase 1 and 2a results.

The Science Behind AEF0117: A New Approach to Managing Cannabis Use Disorder

Delve into the scientific underpinnings of AEF0117, a novel CB1 receptor modulator developed by NINGBO INNO PHARMCHEM CO.,LTD., and its impact on treating Cannabis Use Disorder (CUD). Understand its mechanism, clinical trial outcomes, and its place in future addiction therapies.

Understanding AEF0117: A New Frontier in Treating Cannabis Use Disorder

Explore the science behind AEF0117, a novel CB1 receptor modulator, and its potential to transform the treatment landscape for Cannabis Use Disorder (CUD). Learn about its unique mechanism, clinical trial results, and future prospects from NINGBO INNO PHARMCHEM CO.,LTD.